Randomized controlled trial of screening for hepatocellular carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-03-20

AUTHORS

Bo-Heng Zhang, Bing-Hui Yang, Zhao-You Tang

ABSTRACT

Purpose Screening for hepatocellular carcinoma (HCC) has been conducted for over 20 years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.Methods This study included 18,816 people, aged 35–59 years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6 months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.Results The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41–0.98).Conclusions Our finding indicated that biannual screening reduced HCC mortality by 37%. More... »

PAGES

417-422

References to SciGraph publications

  • 1997-06. Prospective study of early detection for primary liver cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0

    DOI

    http://dx.doi.org/10.1007/s00432-004-0552-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1005026117

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15042359


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Hepatocellular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "China", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Incidence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mass Screening", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Staging", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ultrasonography", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Urban Population", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "alpha-Fetoproteins", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China", 
              "id": "http://www.grid.ac/institutes/grid.413087.9", 
              "name": [
                "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhang", 
            "givenName": "Bo-Heng", 
            "id": "sg:person.0741146613.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741146613.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China", 
              "id": "http://www.grid.ac/institutes/grid.413087.9", 
              "name": [
                "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yang", 
            "givenName": "Bing-Hui", 
            "id": "sg:person.0761714654.79", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761714654.79"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China", 
              "id": "http://www.grid.ac/institutes/grid.413087.9", 
              "name": [
                "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tang", 
            "givenName": "Zhao-You", 
            "id": "sg:person.015352132727.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015352132727.21"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf01438313", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023430516", 
              "https://doi.org/10.1007/bf01438313"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-03-20", 
        "datePublishedReg": "2004-03-20", 
        "description": "Purpose Screening for hepatocellular carcinoma (HCC) has been conducted for over 20\u00a0years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.Methods This study included 18,816 people, aged 35\u201359\u00a0years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6\u00a0months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.Results The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41\u20130.98).Conclusions Our finding indicated that biannual screening reduced HCC mortality by 37%.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00432-004-0552-0", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1313647", 
            "issn": [
              "0171-5216", 
              "1432-1335"
            ], 
            "name": "Journal of Cancer Research and Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "130"
          }
        ], 
        "keywords": [
          "hepatocellular carcinoma", 
          "HCC mortality", 
          "control group", 
          "screened group", 
          "hepatitis B virus infection", 
          "number of HCC", 
          "subclinical hepatocellular carcinoma", 
          "primary outcome measure", 
          "mortality rate ratios", 
          "group participants", 
          "health-care facilities", 
          "HCC mortality rates", 
          "chronic hepatitis", 
          "screening group", 
          "ultrasonography examination", 
          "virus infection", 
          "outcome measures", 
          "biannual screening", 
          "AFP test", 
          "mortality rate", 
          "mortality", 
          "rate ratio", 
          "carcinoma", 
          "urban Shanghai", 
          "screening", 
          "participants", 
          "group", 
          "conclusive evidence", 
          "hepatitis", 
          "resection", 
          "years", 
          "infection", 
          "trials", 
          "months", 
          "risk", 
          "control", 
          "study", 
          "examination", 
          "people", 
          "conclusion", 
          "percent", 
          "aim", 
          "findings", 
          "evidence", 
          "history", 
          "time", 
          "measures", 
          "rate", 
          "test", 
          "effect", 
          "number", 
          "ratio", 
          "facilities", 
          "results", 
          "Shanghai", 
          "method", 
          "China", 
          "Purpose Screening", 
          "B virus infection", 
          "Screening group participants", 
          "small HCC 39", 
          "HCC 39", 
          "survival rate 65.9", 
          "rate 65.9"
        ], 
        "name": "Randomized controlled trial of screening for hepatocellular carcinoma", 
        "pagination": "417-422", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1005026117"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00432-004-0552-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15042359"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00432-004-0552-0", 
          "https://app.dimensions.ai/details/publication/pub.1005026117"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_394.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00432-004-0552-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    208 TRIPLES      22 PREDICATES      107 URIs      98 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00432-004-0552-0 schema:about N0161c067a27943d7b7cc5ae33384383f
    2 N0bb776a7b29f4613a94828ebe47fe0e0
    3 N35536ae7e3664b60a00cf3c9cc43dca7
    4 N415cf6ebb3c44dbead36cc2068b3e9af
    5 N4651ddc2c7694d159483ce035cb736a0
    6 N4de35e5d0c90400e844023fbf67c5af2
    7 N6c23b94dbf0c4a98a110e1de91d2d54f
    8 N8dc828695e7645ce91a1ea15bafa3b34
    9 N9452b6c235ef44c3bdae35271807f9d0
    10 N9a128401ec8b49c2acbbf266081641f0
    11 Na4f2f9c9ee95476aa231440c2d8dfcf0
    12 Nb1b01c7af38e48f6a3a8e25ba5ec2ff8
    13 Nbb49270e0db5453ca34273c66eae39ad
    14 Nd278ecaf35f548a6a4f5b37c049629c5
    15 Nf2587441a83f49c5bb1b00fc2714464e
    16 Nf9b101b795914bcfb116f3cb7c08dd67
    17 anzsrc-for:11
    18 anzsrc-for:1117
    19 schema:author N13d3bc2dfe9741a3a4fa67c835b7193b
    20 schema:citation sg:pub.10.1007/bf01438313
    21 schema:datePublished 2004-03-20
    22 schema:datePublishedReg 2004-03-20
    23 schema:description Purpose Screening for hepatocellular carcinoma (HCC) has been conducted for over 20 years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.Methods This study included 18,816 people, aged 35–59 years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6 months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.Results The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41–0.98).Conclusions Our finding indicated that biannual screening reduced HCC mortality by 37%.
    24 schema:genre article
    25 schema:inLanguage en
    26 schema:isAccessibleForFree false
    27 schema:isPartOf N57b6888ccc734a9e851c7fc5e3ac3f4e
    28 Nb5b6e7f44f194aa5b1673b2637d963bd
    29 sg:journal.1313647
    30 schema:keywords AFP test
    31 B virus infection
    32 China
    33 HCC 39
    34 HCC mortality
    35 HCC mortality rates
    36 Purpose Screening
    37 Screening group participants
    38 Shanghai
    39 aim
    40 biannual screening
    41 carcinoma
    42 chronic hepatitis
    43 conclusion
    44 conclusive evidence
    45 control
    46 control group
    47 effect
    48 evidence
    49 examination
    50 facilities
    51 findings
    52 group
    53 group participants
    54 health-care facilities
    55 hepatitis
    56 hepatitis B virus infection
    57 hepatocellular carcinoma
    58 history
    59 infection
    60 measures
    61 method
    62 months
    63 mortality
    64 mortality rate
    65 mortality rate ratios
    66 number
    67 number of HCC
    68 outcome measures
    69 participants
    70 people
    71 percent
    72 primary outcome measure
    73 rate
    74 rate 65.9
    75 rate ratio
    76 ratio
    77 resection
    78 results
    79 risk
    80 screened group
    81 screening
    82 screening group
    83 small HCC 39
    84 study
    85 subclinical hepatocellular carcinoma
    86 survival rate 65.9
    87 test
    88 time
    89 trials
    90 ultrasonography examination
    91 urban Shanghai
    92 virus infection
    93 years
    94 schema:name Randomized controlled trial of screening for hepatocellular carcinoma
    95 schema:pagination 417-422
    96 schema:productId N0db4308e2dcf4d8cb31f68e1826fba78
    97 N72abfd15a8ba4b6e8b4a3223de3b9c49
    98 N96c57affbf5c410f84dd78f63f86801e
    99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005026117
    100 https://doi.org/10.1007/s00432-004-0552-0
    101 schema:sdDatePublished 2022-01-01T18:14
    102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    103 schema:sdPublisher Nbdfe25f0fe884b4e8365fcbbb4ed2b6f
    104 schema:url https://doi.org/10.1007/s00432-004-0552-0
    105 sgo:license sg:explorer/license/
    106 sgo:sdDataset articles
    107 rdf:type schema:ScholarlyArticle
    108 N0161c067a27943d7b7cc5ae33384383f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Humans
    110 rdf:type schema:DefinedTerm
    111 N0bb776a7b29f4613a94828ebe47fe0e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Adult
    113 rdf:type schema:DefinedTerm
    114 N0db4308e2dcf4d8cb31f68e1826fba78 schema:name dimensions_id
    115 schema:value pub.1005026117
    116 rdf:type schema:PropertyValue
    117 N13d3bc2dfe9741a3a4fa67c835b7193b rdf:first sg:person.0741146613.54
    118 rdf:rest Nf930cb5baaf04da3bbe1e5cade981e42
    119 N35536ae7e3664b60a00cf3c9cc43dca7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Male
    121 rdf:type schema:DefinedTerm
    122 N3ef0570dc787437ca6c79ad10ddc5ba0 rdf:first sg:person.015352132727.21
    123 rdf:rest rdf:nil
    124 N415cf6ebb3c44dbead36cc2068b3e9af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Liver Neoplasms
    126 rdf:type schema:DefinedTerm
    127 N4651ddc2c7694d159483ce035cb736a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Female
    129 rdf:type schema:DefinedTerm
    130 N4de35e5d0c90400e844023fbf67c5af2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Ultrasonography
    132 rdf:type schema:DefinedTerm
    133 N57b6888ccc734a9e851c7fc5e3ac3f4e schema:volumeNumber 130
    134 rdf:type schema:PublicationVolume
    135 N6c23b94dbf0c4a98a110e1de91d2d54f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Mass Screening
    137 rdf:type schema:DefinedTerm
    138 N72abfd15a8ba4b6e8b4a3223de3b9c49 schema:name pubmed_id
    139 schema:value 15042359
    140 rdf:type schema:PropertyValue
    141 N8dc828695e7645ce91a1ea15bafa3b34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Biomarkers, Tumor
    143 rdf:type schema:DefinedTerm
    144 N9452b6c235ef44c3bdae35271807f9d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name China
    146 rdf:type schema:DefinedTerm
    147 N96c57affbf5c410f84dd78f63f86801e schema:name doi
    148 schema:value 10.1007/s00432-004-0552-0
    149 rdf:type schema:PropertyValue
    150 N9a128401ec8b49c2acbbf266081641f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Urban Population
    152 rdf:type schema:DefinedTerm
    153 Na4f2f9c9ee95476aa231440c2d8dfcf0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Neoplasm Staging
    155 rdf:type schema:DefinedTerm
    156 Nb1b01c7af38e48f6a3a8e25ba5ec2ff8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Survival Rate
    158 rdf:type schema:DefinedTerm
    159 Nb5b6e7f44f194aa5b1673b2637d963bd schema:issueNumber 7
    160 rdf:type schema:PublicationIssue
    161 Nbb49270e0db5453ca34273c66eae39ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name alpha-Fetoproteins
    163 rdf:type schema:DefinedTerm
    164 Nbdfe25f0fe884b4e8365fcbbb4ed2b6f schema:name Springer Nature - SN SciGraph project
    165 rdf:type schema:Organization
    166 Nd278ecaf35f548a6a4f5b37c049629c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Carcinoma, Hepatocellular
    168 rdf:type schema:DefinedTerm
    169 Nf2587441a83f49c5bb1b00fc2714464e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Incidence
    171 rdf:type schema:DefinedTerm
    172 Nf930cb5baaf04da3bbe1e5cade981e42 rdf:first sg:person.0761714654.79
    173 rdf:rest N3ef0570dc787437ca6c79ad10ddc5ba0
    174 Nf9b101b795914bcfb116f3cb7c08dd67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Middle Aged
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Medical and Health Sciences
    179 rdf:type schema:DefinedTerm
    180 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    181 schema:name Public Health and Health Services
    182 rdf:type schema:DefinedTerm
    183 sg:journal.1313647 schema:issn 0171-5216
    184 1432-1335
    185 schema:name Journal of Cancer Research and Clinical Oncology
    186 schema:publisher Springer Nature
    187 rdf:type schema:Periodical
    188 sg:person.015352132727.21 schema:affiliation grid-institutes:grid.413087.9
    189 schema:familyName Tang
    190 schema:givenName Zhao-You
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015352132727.21
    192 rdf:type schema:Person
    193 sg:person.0741146613.54 schema:affiliation grid-institutes:grid.413087.9
    194 schema:familyName Zhang
    195 schema:givenName Bo-Heng
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741146613.54
    197 rdf:type schema:Person
    198 sg:person.0761714654.79 schema:affiliation grid-institutes:grid.413087.9
    199 schema:familyName Yang
    200 schema:givenName Bing-Hui
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761714654.79
    202 rdf:type schema:Person
    203 sg:pub.10.1007/bf01438313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023430516
    204 https://doi.org/10.1007/bf01438313
    205 rdf:type schema:CreativeWork
    206 grid-institutes:grid.413087.9 schema:alternateName Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China
    207 schema:name Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China
    208 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...